Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Cash (2016 - 2025)

Cytosorbents (CTSO) has disclosed Change in Cash for 14 consecutive years, with -$2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 3.89% year-over-year to -$2.7 million, compared with a TTM value of -$3.1 million through Sep 2025, down 246.6%, and an annual FY2024 reading of -$5.9 million, up 28.79% over the prior year.
  • Change in Cash was -$2.7 million for Q3 2025 at Cytosorbents, down from -$1.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $5.6 million in Q4 2023 and bottomed at -$12.9 million in Q2 2022.
  • Average Change in Cash over 5 years is -$3.3 million, with a median of -$3.0 million recorded in 2021.
  • The sharpest move saw Change in Cash crashed 349.73% in 2022, then soared 1465.95% in 2023.
  • Year by year, Change in Cash stood at -$7.2 million in 2021, then skyrocketed by 94.35% to -$407672.0 in 2022, then skyrocketed by 1465.95% to $5.6 million in 2023, then tumbled by 143.17% to -$2.4 million in 2024, then fell by 10.97% to -$2.7 million in 2025.
  • Business Quant data shows Change in Cash for CTSO at -$2.7 million in Q3 2025, -$1.4 million in Q2 2025, and $3.3 million in Q1 2025.